# Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion

Study · id `cardio:ct-nct07335107` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07335107](<https://clinicaltrials.gov/study/NCT07335107>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07335107

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 564 participants.

## Technical summary

Registry record NCT07335107. Randomized; no masking; primary purpose treatment. Start 2026-01-12 (anticipated); primary completion 2027-01-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 564 participants (planned count; ClinicalTrials.gov record NCT07335107, source copy `cardio:ctgov-nct07335107-2026-01-13`, retrieved 2026-10-26)
- Planned start: 2026-01-12 (anticipated) (ClinicalTrials.gov record NCT07335107, source copy `cardio:ctgov-nct07335107-2026-01-13`, retrieved 2026-10-26)
- Primary completion: 2027-01-31 (anticipated) (ClinicalTrials.gov record NCT07335107, source copy `cardio:ctgov-nct07335107-2026-01-13`, retrieved 2026-10-26)
- Completion: 2027-04-30 (anticipated) (ClinicalTrials.gov record NCT07335107, source copy `cardio:ctgov-nct07335107-2026-01-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07335107, source copy `cardio:ctgov-nct07335107-2026-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07335107-2026-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Intravenous Tirofiban After Bridging Therapy for Acute Stroke With Atherosclerotic Large Artery Occlusion
- Acronym: RESCUE-AS
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Intravenous Tirofiban
- Intervention (Drug): Standard Medical Therapy
- Lead sponsor: Beijing Tiantan Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

## Provenance

Content hash: c393ebfa543cc608535854af93180f21323a09cedba709b7614c6ed6b6da6e02
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
